Skip to main content
SpringerLink
Log in

Indacaterol worth its cost for COPD in the UK

  • Non-clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. This study was funded by Novartis Pharmaceuticals UK Limited, the manufacturer of Onbrez Breezhaler.

Reference

  • Price D, et al. A UK-Based Cost-Utility Analysis of Indacaterol, A Once-Daily Maintenance Bronchodilator for Patients with COPD, Using Real World Evidence on Resource Use. Applied Health Economics and Health Policy : 26 Mar 2013. Available from: URL: http://dx.doi.org/10.1007/s40258-013-0021-5

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Indacaterol worth its cost for COPD in the UK. PharmacoEcon Outcomes News 676, 8 (2013). https://doi.org/10.1007/s40274-013-0325-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0325-6

Search

Navigation